Track Novartis AG — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Novartis AG NOTA.F Open Novartis AG in new tab

125.00 EUR
P/E
21.01
EPS
5.95
Yield
3.43%
P/B
6.05
ROE
34.93
Beta
0.49
Loading chart...
Key Metrics
P/E21.01
EPS5.95
Book Value20.65
Price to Book6.05
Debt/Equity120.73
% Insiders0.048%
Growth
Revenue Growth-0.01%
Earnings Growth-0.09%
Estimates
Forward P/E18.52
Forward EPS6.75
Dividend
Dividend Yield3.43%
Annual dividends4.15 EUR
Ex-Div. DateMarch 11, 2026
Payout67.91%
5y avg Yield3.54%

DCF Valuation

Tweak assumptions to recompute fair value for Novartis AG (NOTA.F)
Currency: EUR
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result

Fair Value (DCF)
Current Price
Upside
WACC
Terminal PV
Σ PV of FCFs
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

Novartis AG Logo Novartis AG Analysis (NOTA.F)

Switzerland Health Care Official Website Stock

Is Novartis AG a good investment? Novartis AG (NOTA.F) is currently trading at 125.00 EUR.

In terms of valuation, the stock trades at a P/E ratio of 21.01. This valuation is generally in line with the broader market.

For income investors, Novartis AG pays a dividend yield of 3.43%. With a payout ratio of 68%, the dividend appears sustainable.

Investor FAQ

Does Novartis AG pay a dividend?

Yes, it pays an annual dividend of 4.15 EUR (3.43% yield).

What asset class is Novartis AG?

Novartis AG is classified as a Stock. You can compare it against 10 other assets in the "Related Symbols" list on this page.

Company Profile

Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocytopenia (ITP), thrombocytopenia, and patients with severe aplastic anemia (SAA); Tafinlar+Mekinist, an oral combination therapy to treat patients with certain types of cancers; and Jakavi for the treatment of myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease (GvHD). It also provides Tasigna to treat philadelphia chromosomepositive chronic myeloid leukemia in the chronic and/or accelerated phase; Xolair for the treatment of allergic asthma and nasal polyps or severe chronic rhinosi nusitis with nasal polyps; Ilaris to treat fever syndromes, Still's disease, and acute gouty arthritis; Pluvicto to treat prostatespecific membrane anti genpositive metastatic castrationresistant prostate cancer; Sandostatin SC and Sandostatin LAR to treat acromegaly carcinoid tumors and other types of functional gastro intestinal and pancreatic neuroendocrine tumors; Zolgensma for the treatment of genetic root cause of spinal muscular atrophy; Lucentis; Leqvio to reduce LDL cholesterol; Lutathera; Scemblix; and Fabhalta. The company focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, oncology, and hematology. It has a license and collaboration agreement with Alnylam Pharmaceuticals, Inc. to develop, manufacture, and commercialize Leqvio (inclisiran), a therapy to reduce LDL cholesterol. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.

Exchange Ticker
BUE (Argentina) NVS.BA
BUE (Argentina) NVSD.BA
IOB (United Kingdom) 0QLR.IL
FRA (Germany) NOTA.F
STU (Germany) NOTA.SG
SAO (Brazil) N1VS34.SA
MEX (Mexico) NVSN.MX
PNK (United States) NVSEF
EBS (Ireland) NOVN.SW
NYQ (United States) NVS
Dividend Yield

3.43% (5y avg: 3.54%)

Annual Dividends

4.15 EUR

Next ex. div date

March 11, 2026

Payout Ratio

67.91%

Historical Dividends
Year Total Dividends
2027 4.33 EUR
2026 4.12 EUR
2025 3.42 EUR
2024 3.20 EUR
2023 2.99 EUR
2022 2.84 EUR
2021 2.74 EUR
2020 2.64 EUR
2019 2.42 EUR
2018 2.51 EUR
2017 2.32 EUR
2016 2.32 EUR
2015 2.28 EUR
2014 2.36 EUR
2013 2.16 EUR
2012 2.12 EUR
2011 2.02 EUR

Yearly aggregated dividends

Dividends

Novartis AG
Mar 11, 2026 Paid
Dividend
4.124793 EUR

Historical Split Corporate Actions

Trades
Trade History
No trades yet
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion